Assessment of outcome predictors after first attack of optic neuritis

Canadian Journal of Neurological Sciences

Volumn 38, Issue 6, 2011, Pages 887-895

  Mamarabadi, Mansoureh ^a   Razjouyan, Hadie ^b   Mohammadi, Fatemeh ^a   Moghaddasi, Mehdi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; CHILD; CORTICOSTEROID THERAPY; DEMOGRAPHY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IDIOPATHIC DISEASE; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE;

EID: 80155177833     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100012488     Document Type: Article

References (38)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000; 343(13):938-52.
2. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010; 9(7):727-39.
3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010; 9(5):A387-94.
4. Poppe AY, Wolfson C, Zhu B. Prevalence of multiple sclerosis in Canada: a systematic review. Can J Neurol Sci. 2008; 35(5): 593-601.
5. Beck CA, Metz LM, Svenson LW, Pattern SB. Regional variation of multiple sclerosis prevalence in canada. Mult Scler. 2005; 11 (5):516-9. (Pubitemid 41387694)
6. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4(5):281-8. (Pubitemid 40545039)
7. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008; 131(Pt 3):808-17. (Pubitemid 351294716)
8. Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wolheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005; 252(4):396-402. (Pubitemid 40576901)
9. Corona-Vazquez T, Ruiz-Sandoval J, Arriada-Mendicoa N. Optic neuritis progressing to multiple sclerosis. Acta Neurol Scand. 1997; 95(2):85-9. (Pubitemid 27107086)
10. Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry. 1987; 50(6):758-65. (Pubitemid 17076291)
11. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999; 246(9):770-5. (Pubitemid 29467151)
12. Ebers GC, Sadovnick AD, Dyment DA, Yee IM, Willer CJ, Risch N. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet. 2004; 363(9423):1773-4. (Pubitemid 38698382)
13. Hirst C, Ingram G, Pickersgill T, Swingler R, Compston DA, Robertson NP. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry. 2009; 80(4):386-91.
14. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008; 71(2):129-35.
15. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009; 73(9):696-701.
16. Hawkes CH. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler. 2007; 13(5):610-5. (Pubitemid 46939526)
17. Kurtzke JF. Geographic distribution of multiple sclerosis: An update with special reference to Europe and the Mediterranean region. Acta Neurol Scand. 1980; 62(2):65-80. (Pubitemid 10048468)
18. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis-observations from Norway. Neuroepidemiology. 2008; 30(3):140-6. (Pubitemid 351667793)
19. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004; 62(1):60-5. (Pubitemid 38082871)
20. Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005; 330(7483):120.
21. Lin YC, Yen MY, Hsu WM, Lee HC, Wang AG. Low conversion rate to multiple sclerosis in idiopathic optic neuritis patients in Taiwan. Jpn J Ophthalmol. 2006; 50(2):170-5.
22. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008; 65(6):727-32.
23. Kazim SF, Islam M, Khan M, Hameed B, Shafqat S. Risk of multiple sclerosis after idiopathic optic neuritis in a Pakistani population. Can J Neurol Sci. 2010; 37(2):258-63.
24. Balashov KE, Pal G, Rosenberg ML. Optic neuritis incidence is increased in spring months in patients with asymptomatic demyelinating lesions. Mult Scler. 2010; 16(2):252-4.
25. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI. Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group. Arch Neurol. 1993; 50(8): 841-6.
26. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7.
27. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-6. (Pubitemid 41746873)
28. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999; 52(7):1479-84. (Pubitemid 29190544)
29. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998; 121 (Pt 3):495-503. (Pubitemid 28116346)
30. Amirzargar AA, Tabasi A, Khosravi F, et al. Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4-year follow-up study. Eur J Neurol. 2005; 12(1):25-30.
31. Hutchinson WM. Acute optic neuritis and the prognosis for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1976; 39(3): 283-9.
32. Jacobs LD, Kaba SE, Miller CM, Priore RL, Brownscheidle CM. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol. 1997; 41(3):392-8. (Pubitemid 27114051)
33. Vedula SS, Brodney-Folse S, Gal RL, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2007; 24(1): CD001430.
34. Isayama Y, Takahashi T, Shimoyoma T, Yamadori A. Acute optic neuritis and multiple sclerosis. Neurology. 1982; 32(1):73-6. (Pubitemid 12205268)
35. Hely MA, McManis PG, Doran TJ, Walsh JC, Mcleod JG. Acute optic neuritis: a prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1986; 49(10):1125-30. (Pubitemid 16028693)
36. Rizzo JF, 3rd, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988; 38(2):185-90.
37. Soderstrom M. Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand. 2001; 79(3):223-7. (Pubitemid 32577302)
38. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology. 1995; 45(2):244-50.